We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

160 hedge funds and large institutions have $2.41B invested in Intercept Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 57 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 57

7% less funds holding

Funds holding: 172160 (-12)

13% less capital invested

Capital invested by funds: $2.77B → $2.41B (-$369M)

28% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 39

53% less call options, than puts

Call options by funds: $76.9M | Put options by funds: $163M

Holders
160
Holders Change
-12
Holders Change %
-6.98%
% of All Funds
4.26%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
28
Increased
53
Reduced
57
Closed
39
Calls
$76.9M
Puts
$163M
Net Calls
-$85.7M
Net Calls Change
-$55.7M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
51
T. Rowe Price Associates
Maryland
$3.03M -$37.1M -314,171 -93%
PAMU
52
Pictet Asset Management (UK)
United Kingdom
$2.83M -$3.24M -27,444 -52%
ProShare Advisors
53
ProShare Advisors
Maryland
$2.37M -$209K -1,774 -9%
State Board of Administration of Florida Retirement System
54
State Board of Administration of Florida Retirement System
Florida
$2.33M -$213K -1,800 -9%
GH
55
GAM Holding
Switzerland
$2.25M
EMFAT
56
Emerald Mutual Fund Advisers Trust
Pennsylvania
$2.24M -$1.05M -8,930 -34%
Credit Agricole
57
Credit Agricole
France
$2.18M -$30.3M -256,723 -94%
D.E. Shaw & Co
58
D.E. Shaw & Co
New York
$2.12M +$1.95M +16,493 New
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$2.01M -$27.3K -231 -1%
FO
60
FT Options
Illinois
$1.97M +$1.81M +15,314 New
TA
61
Teachers Advisors
New York
$1.8M
Principal Financial Group
62
Principal Financial Group
Iowa
$1.76M -$3.42K -29 -0.2%
BG
63
Bellevue Group
Switzerland
$1.73M +$1.59M +13,500 New
VKH
64
Virtu KCG Holdings
New York
$1.71M +$818K +6,926 +108%
BG
65
BlackRock Group
United Kingdom
$1.68M +$258K +2,188 +20%
Jacobs Levy Equity Management
66
Jacobs Levy Equity Management
New Jersey
$1.68M +$1.54M +13,040 New
Allianz Asset Management
67
Allianz Asset Management
Germany
$1.57M +$17.7K +150 +1%
State of Wisconsin Investment Board
68
State of Wisconsin Investment Board
Wisconsin
$1.44M -$55.5K -470 -4%
Point72 Asset Management
69
Point72 Asset Management
Connecticut
$1.32M +$1.22M +10,300 New
MC
70
Marcus Capital
Illinois
$1.32M +$1.21M +10,250 New
UBS Group
71
UBS Group
Switzerland
$1.31M -$1.76M -14,875 -59%
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$1.31M -$217K -1,840 -15%
RSCM
73
Rock Springs Capital Management
Maryland
$1.28M -$649K -5,500 -35%
Macquarie Group
74
Macquarie Group
Australia
$1.27M +$710K +6,012 +155%
PA
75
Profund Advisors
Maryland
$1.25M -$281K -2,383 -20%

ICPT Hedge Fund Activity: Q1 2016 in Review

160 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2016, worth a combined $2.41B — down 13% from $2.77B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of ICPT and 28 opened new positions — a net loss of 11 holders — while 57 trimmed existing stakes and 53 added.

The largest buyer was Carmignac Gestion, adding an estimated $41M. The largest seller was First Trust Advisors, cutting an estimated $40.1M.

  • 160 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2016, down from 172 in Q4 2015.
  • Funds reported $2.41B of Intercept Pharmaceuticals, Inc. stock for Q1 2016, down 13% quarter-over-quarter.
  • 28 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2016 and 39 closed out, a net change of -11 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2016 was Carmignac Gestion, an estimated $41M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2016 was First Trust Advisors, an estimated $40.1M sold.

Based on aggregated 13F filings for Q1 2016.